Trial Profile
Open, phase IIIb, multicentric, safety and reactogenicity study of GlaxoSmithKline Biologicals' reduced antigen content combined diphtheria-tetanus-acellular pertussis vaccine (Boostrix) administered as a booster dose to healthy children 4-6 years of age according to the international recommended prescribing information
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 06 Nov 2006 New trial record.